Management of Infections in Cirrhosis
All cirrhotic patients with ascites admitted to hospital must undergo immediate diagnostic paracentesis to rule out spontaneous bacterial peritonitis (SBP), even without symptoms of infection, and empirical antibiotics should be started immediately when ascitic neutrophil count exceeds 250/mm³. 1
Diagnostic Approach
When to Perform Diagnostic Paracentesis
Perform diagnostic paracentesis urgently in the following scenarios:
- Every hospital admission in cirrhotic patients with ascites, regardless of symptoms 1, 2
- Fever or signs of systemic inflammation
- GI bleeding
- Shock
- Gastrointestinal symptoms
- Hepatic encephalopathy
- Worsening liver or renal function 1
Diagnostic Criteria
- Gold standard: Ascitic neutrophil count >250/mm³ establishes SBP diagnosis 1
- Can use manual microscopy or automated flow cytometry
- Culture technique: Inoculate at least 10 mL of ascitic fluid into blood culture bottles at bedside before antibiotics (increases sensitivity to >90%) 1, 2
- Obtain simultaneous blood cultures to increase organism isolation 2
Empirical Antibiotic Treatment
Initial Therapy Selection
The choice of empirical antibiotics must be guided by the clinical context and local resistance patterns:
- Community-acquired SBP in low-resistance settings: IV cefotaxime 2g every 12 hours or ceftriaxone 1, 2
- Healthcare-associated or nosocomial SBP: Broader spectrum coverage due to increasing multidrug-resistant organisms (MDROs) 1, 2
- Critically ill patients or recent hospitalization: Consider broader coverage given MDRO prevalence now reaching 35% of infections 2
Critical timing: Start antibiotics immediately upon diagnosis—do not wait for culture results 1, 2
Treatment Monitoring
Consider repeat paracentesis at 48 hours in patients with:
- Inadequate clinical response
- Suspected secondary bacterial peritonitis 1
Prophylactic Antibiotic Strategies
Secondary Prophylaxis (After SBP Episode)
Patients who recover from SBP should receive long-term prophylaxis with: 1
- Norfloxacin 400 mg once daily (preferred), OR
- Ciprofloxacin 500 mg once daily, OR
- Co-trimoxazole (800 mg sulfamethoxazole/160 mg trimethoprim) once daily
Primary Prophylaxis
Offer to high-risk patients with ascitic protein <1.5 g/dL, though evidence quality is low and risks/benefits must be discussed with patients 1
Prophylaxis for GI Bleeding
Patients with GI bleeding and ascites must receive prophylactic antibiotics (cefotaxime widely studied, but choose based on local resistance data) to prevent SBP development—this has strong evidence 1
Important Clinical Pitfalls
Antimicrobial Resistance Considerations
The epidemiology has shifted dramatically: gram-positive organisms and MDROs now represent a substantial proportion of infections, particularly in nosocomial settings 2. Traditional third-generation cephalosporins may be inadequate in these contexts. Inappropriate initial antimicrobial therapy in septic shock increases mortality risk by 10-fold 2.
Proton Pump Inhibitor Use
Long-term PPI use may increase SBP risk—carefully assess indications for continued use 1
Microbiological Patterns
- ~60% gram-negative bacteria (E. coli most common, then Klebsiella)
- Increasing gram-positive organisms (S. aureus, Enterococcus species)
- Fungi represent <5% of infections
- Spontaneous infections are typically monobacterial 2
Algorithmic Approach Summary
- On admission: Immediate diagnostic paracentesis for all ascites patients
- If neutrophils >250/mm³: Start empirical IV antibiotics immediately (cefotaxime 2g q12h in community-acquired/low-resistance settings; broader coverage for nosocomial/MDRO risk)
- Culture: Bedside inoculation into blood culture bottles before antibiotics
- Monitor: Consider repeat tap at 48 hours if inadequate response
- After recovery: Initiate secondary prophylaxis (norfloxacin 400mg daily or alternatives)
- Special situations: Prophylactic antibiotics for all GI bleeding with ascites
The evidence strongly emphasizes that early diagnosis and immediate appropriate antibiotic therapy are critical to reducing mortality in this high-risk population 3, 4, 5. Delays in diagnosis or inadequate initial antimicrobial coverage lead to unfavorable outcomes and increased mortality 2, 3.